Loading tape…Loading tape…
ABT
ABT
ABT
Wall Street analyst optimism for Abbott Laboratories coincides with solid financial metrics, including an annual revenue of $44.33 billion and a market capitalization of $187.44 billion. The company holds a trailing twelve months EPS of 3.11, alongside a P/E ratio of 34.83. Additionally, Abbott demonstrates a free cash flow yield of 4.65% as investors assess its valuation profile.
Based on zacks.comCountdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Absolute Software Co. (ABT.TO) (TSE:ABT) Stock Crosses Above 200 Day Moving Average – What’s Next?
3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades
Abbott Laboratories $ABT Stock: Krilogy Financial LLC Increases Stake
Longleaf Partners Global Fund Q3 2026 Portfolio Review
Medtronic Pays More Today. Abbott Raises Its Dividend Faster.
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.